Cargando…
CRISPR-Cas systems for diagnosing infectious diseases
Infectious diseases are a global health problem affecting billions of people. Developing rapid and sensitive diagnostic tools is key for successful patient management and curbing disease spread. Currently available diagnostics are very specific and sensitive but time-consuming and require expensive...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032595/ https://www.ncbi.nlm.nih.gov/pubmed/33839288 http://dx.doi.org/10.1016/j.ymeth.2021.04.007 |
_version_ | 1783676240138338304 |
---|---|
author | Kostyusheva, Anastasiya Brezgin, Sergey Babin, Yurii Vasilyeva, Irina Glebe, Dieter Kostyushev, Dmitry Chulanov, Vladimir |
author_facet | Kostyusheva, Anastasiya Brezgin, Sergey Babin, Yurii Vasilyeva, Irina Glebe, Dieter Kostyushev, Dmitry Chulanov, Vladimir |
author_sort | Kostyusheva, Anastasiya |
collection | PubMed |
description | Infectious diseases are a global health problem affecting billions of people. Developing rapid and sensitive diagnostic tools is key for successful patient management and curbing disease spread. Currently available diagnostics are very specific and sensitive but time-consuming and require expensive laboratory settings and well-trained personnel; thus, they are not available in resource-limited areas, for the purposes of large-scale screenings and in case of outbreaks and epidemics. Developing new, rapid, and affordable point-of-care diagnostic assays is urgently needed. This review focuses on CRISPR-based technologies and their perspectives to become platforms for point-of-care nucleic acid detection methods and as deployable diagnostic platforms that could help to identify and curb outbreaks and emerging epidemics. We describe the mechanisms and function of different classes and types of CRISPR-Cas systems, including pros and cons for developing molecular diagnostic tests and applications of each type to detect a wide range of infectious agents. Many Cas proteins (Cas3, Cas9, Cas12, Cas13, Cas14 etc.) have been leveraged to create highly accurate and sensitive diagnostic tools combined with technologies of signal amplification and fluorescent, potentiometric, colorimetric, lateral flow assay detection and other. In particular, the most advanced platforms -- SHERLOCK/v2, DETECTR, CARMEN or CRISPR-Chip -- enable detection of attomolar amounts of pathogenic nucleic acids with specificity comparable to that of PCR but with minimal technical settings. Further developing CRISPR-based diagnostic tools promises to dramatically transform molecular diagnostics, making them easily affordable and accessible virtually anywhere in the world. The burden of socially significant diseases, frequent outbreaks, recent epidemics (MERS, SARS and the ongoing COVID-19) and outbreaks of zoonotic viruses (African Swine Fever Virus etc.) urgently need the developing and distribution of express-diagnostic tools. Recently devised CRISPR-technologies represent the unprecedented opportunity to reshape epidemiological surveillance and molecular diagnostics. |
format | Online Article Text |
id | pubmed-8032595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80325952021-04-09 CRISPR-Cas systems for diagnosing infectious diseases Kostyusheva, Anastasiya Brezgin, Sergey Babin, Yurii Vasilyeva, Irina Glebe, Dieter Kostyushev, Dmitry Chulanov, Vladimir Methods Article Infectious diseases are a global health problem affecting billions of people. Developing rapid and sensitive diagnostic tools is key for successful patient management and curbing disease spread. Currently available diagnostics are very specific and sensitive but time-consuming and require expensive laboratory settings and well-trained personnel; thus, they are not available in resource-limited areas, for the purposes of large-scale screenings and in case of outbreaks and epidemics. Developing new, rapid, and affordable point-of-care diagnostic assays is urgently needed. This review focuses on CRISPR-based technologies and their perspectives to become platforms for point-of-care nucleic acid detection methods and as deployable diagnostic platforms that could help to identify and curb outbreaks and emerging epidemics. We describe the mechanisms and function of different classes and types of CRISPR-Cas systems, including pros and cons for developing molecular diagnostic tests and applications of each type to detect a wide range of infectious agents. Many Cas proteins (Cas3, Cas9, Cas12, Cas13, Cas14 etc.) have been leveraged to create highly accurate and sensitive diagnostic tools combined with technologies of signal amplification and fluorescent, potentiometric, colorimetric, lateral flow assay detection and other. In particular, the most advanced platforms -- SHERLOCK/v2, DETECTR, CARMEN or CRISPR-Chip -- enable detection of attomolar amounts of pathogenic nucleic acids with specificity comparable to that of PCR but with minimal technical settings. Further developing CRISPR-based diagnostic tools promises to dramatically transform molecular diagnostics, making them easily affordable and accessible virtually anywhere in the world. The burden of socially significant diseases, frequent outbreaks, recent epidemics (MERS, SARS and the ongoing COVID-19) and outbreaks of zoonotic viruses (African Swine Fever Virus etc.) urgently need the developing and distribution of express-diagnostic tools. Recently devised CRISPR-technologies represent the unprecedented opportunity to reshape epidemiological surveillance and molecular diagnostics. Elsevier Inc. 2022-07 2021-04-09 /pmc/articles/PMC8032595/ /pubmed/33839288 http://dx.doi.org/10.1016/j.ymeth.2021.04.007 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Kostyusheva, Anastasiya Brezgin, Sergey Babin, Yurii Vasilyeva, Irina Glebe, Dieter Kostyushev, Dmitry Chulanov, Vladimir CRISPR-Cas systems for diagnosing infectious diseases |
title | CRISPR-Cas systems for diagnosing infectious diseases |
title_full | CRISPR-Cas systems for diagnosing infectious diseases |
title_fullStr | CRISPR-Cas systems for diagnosing infectious diseases |
title_full_unstemmed | CRISPR-Cas systems for diagnosing infectious diseases |
title_short | CRISPR-Cas systems for diagnosing infectious diseases |
title_sort | crispr-cas systems for diagnosing infectious diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032595/ https://www.ncbi.nlm.nih.gov/pubmed/33839288 http://dx.doi.org/10.1016/j.ymeth.2021.04.007 |
work_keys_str_mv | AT kostyushevaanastasiya crisprcassystemsfordiagnosinginfectiousdiseases AT brezginsergey crisprcassystemsfordiagnosinginfectiousdiseases AT babinyurii crisprcassystemsfordiagnosinginfectiousdiseases AT vasilyevairina crisprcassystemsfordiagnosinginfectiousdiseases AT glebedieter crisprcassystemsfordiagnosinginfectiousdiseases AT kostyushevdmitry crisprcassystemsfordiagnosinginfectiousdiseases AT chulanovvladimir crisprcassystemsfordiagnosinginfectiousdiseases |